Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM.

This is a highly significant finding given the association of RAS pathway mutations and CNS disease at relapse that we previously reported in the IBFM-REZ2002 clinical trial and the fact that in contemporary regimens, the proportion of CNS relapses is increasing. 39 A key question, relevant to MEK inhibitor therapy, is whether

also in 132,142 other papers